Drugs.com - Clinical Trials

SCORPIO-PEP Phase 3 Trial: Ensitrelvir is the First and Only COVID-19 Oral Antiviral to Demonstrate Prevention of COVID-19 as Post Exposure Prophylaxis

OSAKA, Japan, March 13, 2025 – Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) delivered a late-breaking scientific oral presentation at the Conference of...

Mar 18, 2025 - 07:11
 0
SCORPIO-PEP Phase 3 Trial: Ensitrelvir is the First and Only COVID-19 Oral Antiviral to Demonstrate Prevention of COVID-19 as Post Exposure Prophylaxis
OSAKA, Japan, March 13, 2025 – Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) delivered a late-breaking scientific oral presentation at the Conference of...
Read More

Tags:

Previous Article

Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Po...

Next Article

8 Luxury Cars Of 2025 That Burn Rubber & Spark Joy

Related Posts

Lundbeck’s Potential Treatment Amlenetug for Multiple System Atrophy Receives Fast Track Designation From the FDA

Lundbeck’s Potential Treatment Amlenetug for Multiple S...

Feb 17, 2025  0

Icotrokinra Meets Primary Endpoint of Clinical Response in Ulcerative Colitis Study and Shows Potential to Transform the Treatment Paradigm for Patients

Icotrokinra Meets Primary Endpoint of Clinical Response...

Mar 10, 2025  0

Vivani Medical Achieves First Implant and Full Enrollment in the First-in-Human Clinical Trial of GLP-1 Implant NPM-115 in Obese or Overweight Adults

Vivani Medical Achieves First Implant and Full Enrollme...

Mar 18, 2025  0